All In Biotech

Drug Trial Radar · NCT04915287

Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure

Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure: A Prospective Non-randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

476

Planned (sponsor's estimate)

Start

Jun 6, 2021

Primary completion

Jun 30, 2023

Study completion Jul 31, 2023

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, investigators aimed to evaluate the efficacy of Avatrombopag in thrombocytopenic patients with chronic liver disease undergoing an elective invasive procedure through a prospective, non-randomized controlled, multicenter clinical trial. The patients were non-randomly assigned to the Avatrombopag group (119 patients) and the conventional treatment group (357 patients). The primary endpoint was the proportion of patients not requiring prophylactic platelet transfusion or rescue therapy due to bleeding from grouping up to 10 days post-procedure. Second endpoints included the proportion of patients achieving a platelet count of ≥50x10\^9/L and the mean change in platelet count from baseline at the time before the procedure, the proportion of patients requiring platelet transfusion and the mean platelet transfusion units per capita, the incidence of bleeding events (WHO≥2 and requiring rescue therapy), the imaging evaluations of bleeding events, the incidence of adverse events, the changes in life quality between two groups before and after treatment, and the pharmacoeconomic index of two groups. Note: According to the results of interim statistical analysis (200-300 cases), it is up to the sponsor to decide whether to terminate the study in advance or increase the number of included cases at a later stage.

Conditions

  • Thrombocytopenia; Drugs
  • Chronic Liver Disease

Interventions

  • Avatrombopag maleateDrug

    1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure 2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure

  • Platelet transfusionBiological

    Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: platelet transfusion if needed

  • MedicineDrug

    Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients not requiring prophylactic platelet transfusionTime frame: From grouping up to 10 days post-procedure
  2. The proportion of patients not requiring rescue therapy due to bleedingTime frame: From grouping up to 10 days post-procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.